Neuropace/$NPCE
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Neuropace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Ticker
$NPCE
Sector
Primary listing
Employees
209
Headquarters
Website
Neuropace Metrics
BasicAdvanced
$483M
-
-$0.75
1.90
-
Price and volume
Market cap
$483M
Beta
1.9
52-week high
$18.98
52-week low
$7.56
Average daily volume
219K
Financial strength
Current ratio
4.862
Quick ratio
3.823
Long term debt to equity
373.312
Total debt to equity
384.388
Interest coverage (TTM)
-2.26%
Profitability
EBITDA (TTM)
-18.018
Gross margin (TTM)
76.77%
Net profit margin (TTM)
-25.28%
Operating margin (TTM)
-19.21%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
-11.19%
Return on equity (TTM)
-169.27%
Valuation
Price to revenue (TTM)
4.869
Price to book
26.06
Price to tangible book (TTM)
26.06
Price to free cash flow (TTM)
-27.852
Free cash flow yield (TTM)
-3.59%
Free cash flow per share (TTM)
-0.521
Growth
Revenue change (TTM)
24.08%
Earnings per share change (TTM)
-24.00%
3-year revenue growth (CAGR)
29.45%
3-year earnings per share growth (CAGR)
-26.64%
What the Analysts think about Neuropace
Analyst ratings (Buy, Hold, Sell) for Neuropace stock.
Neuropace Financial Performance
Revenues and expenses
Neuropace Earnings Performance
Company profitability
Neuropace News
AllArticlesVideos
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
Business Wire·1 month ago
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
Business Wire·1 month ago
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neuropace stock?
Neuropace (NPCE) has a market cap of $483M as of February 13, 2026.
What is the P/E ratio for Neuropace stock?
The price to earnings (P/E) ratio for Neuropace (NPCE) stock is 0 as of February 13, 2026.
Does Neuropace stock pay dividends?
No, Neuropace (NPCE) stock does not pay dividends to its shareholders as of February 13, 2026.
When is the next Neuropace dividend payment date?
Neuropace (NPCE) stock does not pay dividends to its shareholders.
What is the beta indicator for Neuropace?
Neuropace (NPCE) has a beta rating of 1.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.